BMI assessment

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89